$OTLC
Oncotelic Therapeutics, Inc.

2016 Q2 Form 10-Q Financial Statement

#000119312516582065 Filed on May 06, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2016 Q1 2015 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.300M $1.370M $1.110M
YoY Change -3.7% 23.42% -10.48%
% of Gross Profit
Research & Development $2.374M $1.980M $1.669M
YoY Change 19.84% 18.63% 20.33%
% of Gross Profit
Depreciation & Amortization $0.00 $5.000K $5.000K
YoY Change 0.0% 25.0%
% of Gross Profit
Operating Expenses $3.670M $3.352M $2.777M
YoY Change 10.28% 20.71% 5.67%
Operating Profit -$3.670M -$3.352M -$2.777M
YoY Change 10.28% 20.71% 5.67%
Interest Expense $30.00K $30.00K $0.00
YoY Change 200.0%
% of Operating Profit
Other Income/Expense, Net $0.00 -$1.000K $2.000K
YoY Change -100.0% -150.0% -166.67%
Pretax Income -$3.640M -$3.330M -$2.770M
YoY Change 9.64% 20.22% 5.32%
Income Tax
% Of Pretax Income
Net Earnings -$3.641M -$3.325M -$2.772M
YoY Change 9.54% 19.95% 5.4%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.14 -$0.13 -$0.13
COMMON SHARES
Basic Shares Outstanding 26.54M shares 26.54M shares 26.54M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q2 2016 Q1 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.34M $22.89M $35.74M
YoY Change -41.55% -35.95% 44.46%
Cash & Equivalents $7.939M $13.02M $35.74M
Short-Term Investments $11.40M $12.61M
Other Short-Term Assets $1.040M $1.300M $760.0K
YoY Change 121.28% 71.05% 1753.66%
Inventory
Prepaid Expenses $755.0K
Receivables
Other Receivables
Total Short-Term Assets $20.38M $24.18M $36.49M
YoY Change -39.29% -33.73% 45.12%
LONG-TERM ASSETS
Property, Plant & Equipment $19.00K $25.00K $32.00K
YoY Change -54.76% -21.88% 0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $33.00K $33.00K $33.00K
YoY Change 0.0% 0.0%
Total Long-Term Assets $52.00K $58.00K $65.00K
YoY Change -30.67% -10.77% -36.27%
TOTAL ASSETS
Total Short-Term Assets $20.38M $24.18M $36.49M
Total Long-Term Assets $52.00K $58.00K $65.00K
Total Assets $20.43M $24.24M $36.56M
YoY Change -39.27% -33.69% 44.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $501.0K $475.0K $189.0K
YoY Change 181.46% 151.32% -56.25%
Accrued Expenses $1.120M $1.550M $840.0K
YoY Change 13.13% 84.52% -12.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.617M $2.024M $1.029M
YoY Change 38.68% 96.7% -26.24%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.617M $2.024M $1.029M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.620M $2.020M $1.030M
YoY Change 38.46% 96.12% -26.43%
SHAREHOLDERS EQUITY
Retained Earnings -$271.8M -$268.1M -$253.9M
YoY Change 5.65% 5.59% 5.3%
Common Stock $290.6M $290.4M $289.5M
YoY Change 0.3% 0.31% 9.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.81M $22.22M $35.53M
YoY Change
Total Liabilities & Shareholders Equity $20.43M $24.24M $36.56M
YoY Change -39.27% -33.69% 44.8%

Cashflow Statement

Concept 2016 Q2 2016 Q1 2015 Q1
OPERATING ACTIVITIES
Net Income -$3.641M -$3.325M -$2.772M
YoY Change 9.54% 19.95% 5.4%
Depreciation, Depletion And Amortization $0.00 $5.000K $5.000K
YoY Change 0.0% 25.0%
Cash From Operating Activities -$3.540M -$4.400M -$3.500M
YoY Change 35.11% 25.71% 33.38%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $1.210M -$12.61M
YoY Change
Cash From Investing Activities $1.210M -$12.61M
YoY Change -6150.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $9.207M
YoY Change -15.22%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 9.210M
YoY Change -100.0% -100.0% -54.75%
NET CHANGE
Cash From Operating Activities -3.540M -4.400M -3.500M
Cash From Investing Activities 1.210M -12.61M
Cash From Financing Activities 0.000 0.000 9.210M
Net Change In Cash -2.330M -17.01M 5.710M
YoY Change -12.08% -397.9% -67.79%
FREE CASH FLOW
Cash From Operating Activities -$3.540M -$4.400M -$3.500M
Capital Expenditures $0.00
Free Cash Flow -$3.540M
YoY Change 34.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26544934 shares
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35735000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3861000 shares
CY2016Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000 shares
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
3375000 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.59
CY2016Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26545000 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
865000 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.49
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
9842000 shares
CY2016Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2016Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.37
CY2016Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26545000 shares
CY2016Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2614000 shares
CY2016Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
290086000
CY2016Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
459000
CY2016Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
333000
CY2016Q1 us-gaap Stockholders Equity
StockholdersEquity
22217000
CY2016Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2016Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
475000
CY2016Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-268134000
CY2016Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24241000
CY2016Q1 us-gaap Common Stock Value
CommonStockValue
265000
CY2016Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2024000
CY2016Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1400000
CY2016Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
22886000
CY2016Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
73000
CY2016Q1 us-gaap Assets
Assets
24241000
CY2016Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2016Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0
CY2016Q1 us-gaap Assets Current
AssetsCurrent
24183000
CY2016Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1297000
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10276000
CY2016Q1 us-gaap Short Term Investments
ShortTermInvestments
12610000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
129000
CY2016Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
22886000
CY2016Q1 oxgn Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
757000
CY2016Q1 oxgn Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber
486000 shares
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30031000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2031000 shares
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.01
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26545000 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2695000 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
9842000 shares
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26545000 shares
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
289894000
CY2015Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
636000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
262000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
25350000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
287000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-264809000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27453000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
265000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2103000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33000
CY2015Q4 us-gaap Assets
Assets
27453000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
27390000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
105000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2016Q1 dei Document Type
DocumentType
10-Q
CY2016Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000908259
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27285000
CY2015Q4 oxgn Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
918000
CY2016Q1 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3503000
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0147 pure
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9450 pure
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21095000 shares
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-2772000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
434000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2777000
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
CY2015Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
3000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
88000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5704000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
2777000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
9207000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1669000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9207000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-390000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1108000
CY2015Q1 us-gaap Depreciation
Depreciation
5000
CY2016Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4399000
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M9D
CY2016Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016Q1 dei Amendment Flag
AmendmentFlag
false
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0153 pure
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
112000 shares
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y5M9D
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.32
CY2016Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y8M16D
CY2016Q1 dei Document Period End Date
DocumentPeriodEndDate
2016-03-31
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8899 pure
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.73
CY2016Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016Q1 dei Entity Registrant Name
EntityRegistrantName
OXIGENE INC
CY2016Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with U.S.&#xA0;generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
CY2016Q1 dei Trading Symbol
TradingSymbol
OXGN
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26545000 shares
CY2016Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1942000 shares
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-3325000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1192000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3352000
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2016Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
12610000
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
28000
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
192000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-17009000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
3352000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-12610000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1980000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-79000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1372000
CY2016Q1 us-gaap Depreciation
Depreciation
5000
CY2016Q1 oxgn Number Of Drug Candidates
NumberOfDrugCandidates
2 Candidate
CY2016Q1 oxgn Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted
1942000 shares
CY2016Q1 oxgn Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm
P7Y4M28D
CY2016Q1 oxgn Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term Two
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo
P8Y11M23D
CY2016Q1 oxgn Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice
3.11
CY2016Q1 oxgn Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited
112000 shares

Files In Submission

Name View Source Status
0001193125-16-582065-index-headers.html Edgar Link pending
0001193125-16-582065-index.html Edgar Link pending
0001193125-16-582065.txt Edgar Link pending
0001193125-16-582065-xbrl.zip Edgar Link pending
d119969d10q.htm Edgar Link pending
d119969dex311.htm Edgar Link pending
d119969dex312.htm Edgar Link pending
d119969dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
oxgn-20160331.xml Edgar Link completed
oxgn-20160331.xsd Edgar Link pending
oxgn-20160331_cal.xml Edgar Link unprocessable
oxgn-20160331_def.xml Edgar Link unprocessable
oxgn-20160331_lab.xml Edgar Link unprocessable
oxgn-20160331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending